331 related articles for article (PubMed ID: 23475683)
21. Human cytochrome P450 (CYP) genes: recommendations for the nomenclature of alleles.
Ingelman-Sundberg M; Daly AK; Oscarson M; Nebert DW
Pharmacogenetics; 2000 Feb; 10(1):91-3. PubMed ID: 10739177
[No Abstract] [Full Text] [Related]
22. Estimation of drug-metabolizing capacity by cytochrome P450 genotyping and expression.
Temesvári M; Kóbori L; Paulik J; Sárváry E; Belic A; Monostory K
J Pharmacol Exp Ther; 2012 Apr; 341(1):294-305. PubMed ID: 22262920
[TBL] [Abstract][Full Text] [Related]
23. Macaque cytochromes P450: nomenclature, transcript, gene, genomic structure, and function.
Uno Y; Iwasaki K; Yamazaki H; Nelson DR
Drug Metab Rev; 2011 Aug; 43(3):346-61. PubMed ID: 21303270
[TBL] [Abstract][Full Text] [Related]
24. Characterisation of the xenobiotic-metabolizing Cytochrome P450 expression pattern in human lung tissue by immunochemical and activity determination.
Bernauer U; Heinrich-Hirsch B; Tönnies M; Peter-Matthias W; Gundert-Remy U
Toxicol Lett; 2006 Jul; 164(3):278-88. PubMed ID: 16483733
[TBL] [Abstract][Full Text] [Related]
25. Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation.
Gomes AM; Winter S; Klein K; Turpeinen M; Schaeffeler E; Schwab M; Zanger UM
Pharmacogenomics; 2009 Apr; 10(4):579-99. PubMed ID: 19374516
[TBL] [Abstract][Full Text] [Related]
26. Cytochrome P450-mediated metabolism in the human gut wall.
Thelen K; Dressman JB
J Pharm Pharmacol; 2009 May; 61(5):541-58. PubMed ID: 19405992
[TBL] [Abstract][Full Text] [Related]
27. The human genome project and novel aspects of cytochrome P450 research.
Ingelman-Sundberg M
Toxicol Appl Pharmacol; 2005 Sep; 207(2 Suppl):52-6. PubMed ID: 15993453
[TBL] [Abstract][Full Text] [Related]
28. In vitro assessment of the allelic variants of cytochrome P450.
Hiratsuka M
Drug Metab Pharmacokinet; 2012; 27(1):68-84. PubMed ID: 22041138
[TBL] [Abstract][Full Text] [Related]
29. Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment.
Brockmöller J; Kirchheiner J; Meisel C; Roots I
Pharmacogenomics; 2000 May; 1(2):125-51. PubMed ID: 11256586
[TBL] [Abstract][Full Text] [Related]
30. CYP2D6*11 and challenges in clinical genotyping of the highly polymorphic CYP2D6 gene.
Skierka JM; Walker DL; Peterson SE; O'Kane DJ; Black JL
Pharmacogenomics; 2012 Jun; 13(8):951-4. PubMed ID: 22676198
[TBL] [Abstract][Full Text] [Related]
31. Markers of genetic susceptibility in human environmental hygiene and toxicology: the role of selected CYP, NAT and GST genes.
Thier R; Brüning T; Roos PH; Rihs HP; Golka K; Ko Y; Bolt HM
Int J Hyg Environ Health; 2003 Jun; 206(3):149-71. PubMed ID: 12872524
[TBL] [Abstract][Full Text] [Related]
32. [Current availability of genetic information of drug metabolizing enzymes, particularly on cytochrome P450(CYP)].
Yamazoe Y; Nagata K
Nihon Rinsho; 2001 Aug; 59(8):1614-23. PubMed ID: 11519169
[TBL] [Abstract][Full Text] [Related]
33. Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents.
Murray M
J Pharm Pharmacol; 2006 Jul; 58(7):871-85. PubMed ID: 16805946
[TBL] [Abstract][Full Text] [Related]
34. CYP-nsSNP: a specialized database focused on effect of non-synonymous SNPs on function of CYPs.
Zhang T; Zhou Q; Pang Y; Wang Y; Jin C; Huo J; Liu LA; Wei D
Interdiscip Sci; 2012 Jun; 4(2):83-9. PubMed ID: 22843230
[TBL] [Abstract][Full Text] [Related]
35. Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy.
Preissner SC; Hoffmann MF; Preissner R; Dunkel M; Gewiess A; Preissner S
PLoS One; 2013; 8(12):e82562. PubMed ID: 24340040
[TBL] [Abstract][Full Text] [Related]
36. Genetic polymorphisms associated with antiepileptic metabolism.
Lopez-Garcia MA; Feria-Romero IA; Fernando-Serrano H; Escalante-Santiago D; Grijalva I; Orozco-Suarez S
Front Biosci (Elite Ed); 2014 Jun; 6(2):377-86. PubMed ID: 24896213
[TBL] [Abstract][Full Text] [Related]
37. Challenges in exploring the cytochrome P450 system as a source of variation in canine drug pharmacokinetics.
Martinez MN; Antonovic L; Court M; Dacasto M; Fink-Gremmels J; Kukanich B; Locuson C; Mealey K; Myers MJ; Trepanier L
Drug Metab Rev; 2013 May; 45(2):218-30. PubMed ID: 23432217
[TBL] [Abstract][Full Text] [Related]
38. Cytochrome P450-mediated drug interactions.
Flockhart DA; Oesterheld JR
Child Adolesc Psychiatr Clin N Am; 2000 Jan; 9(1):43-76. PubMed ID: 10674190
[TBL] [Abstract][Full Text] [Related]
39. Cytochromes P450: decision-making tools for personalized therapeutics.
Murray M; Petrovic N
Curr Opin Mol Ther; 2006 Dec; 8(6):480-6. PubMed ID: 17243482
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of human drug metabolizing cytochrome P450 enzymes by plant isoquinoline alkaloids.
Salminen KA; Meyer A; Jerabkova L; Korhonen LE; Rahnasto M; Juvonen RO; Imming P; Raunio H
Phytomedicine; 2011 Apr; 18(6):533-8. PubMed ID: 20851588
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
